Old Mission Investment Co LLC Acquires New Stake in Stryker Corporation $SYK

Old Mission Investment Co LLC bought a new position in shares of Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 2,419 shares of the medical technology company’s stock, valued at approximately $764,000.

A number of other institutional investors have also recently added to or reduced their stakes in the company. VanderPol Investments L.L.C. increased its position in shares of Stryker by 1.4% during the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after purchasing an additional 28 shares during the period. KCM Investment Advisors LLC raised its stake in shares of Stryker by 1.5% in the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock worth $653,000 after buying an additional 28 shares in the last quarter. Rossby Financial LCC lifted its holdings in shares of Stryker by 6.6% in the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock valued at $159,000 after buying an additional 28 shares during the period. Tcfg Wealth Management LLC boosted its stake in Stryker by 2.7% during the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after buying an additional 29 shares in the last quarter. Finally, ICW Investment Advisors LLC boosted its stake in Stryker by 0.6% during the fourth quarter. ICW Investment Advisors LLC now owns 5,096 shares of the medical technology company’s stock valued at $1,791,000 after buying an additional 30 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Argus set a $370.00 target price on Stryker in a report on Thursday, July 9th. UBS Group initiated coverage on shares of Stryker in a report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 price target for the company. Wolfe Research lowered shares of Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. JPMorgan Chase & Co. lowered their price objective on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Finally, BMO Capital Markets assumed coverage on shares of Stryker in a report on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $386.28.

Insider Transactions at Stryker

In other news, insider Dylan Crotty sold 441 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider owned 6,102 shares in the company, valued at $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Debra King sold 826 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 351,267 shares of company stock valued at $118,197,701 over the last ninety days. Corporate insiders own 4.60% of the company’s stock.

Stryker Trading Down 1.6%

Shares of NYSE SYK opened at $302.92 on Friday. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.37. The company has a market cap of $116.19 billion, a price-to-earnings ratio of 31.39, a P/E/G ratio of 1.93 and a beta of 0.76. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The business has a fifty day simple moving average of $328.84 and a 200-day simple moving average of $329.73.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the business posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts predict that Stryker Corporation will post 15.03 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.